Key facts
- Notable investors include Nextech Invest.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Zenith Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Zenith Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Zenith Therapeutics
Developer of a transcription factor modulating drug discovery platform designed to target previously inaccessible oncology pathways through native protein interactions. The company's platform leverages physiological quality control mechanisms to identify transcription factor and E3 ligase pairs with inherent affinity and applies small molecule discovery to modulate these interactions, enabling oncology researchers and pharmaceutical developers to access a previously undruggable class of targets and expand therapeutic development in cancer.
- Sector
- Healthcare
- HQ
- Basel, Switzerland
- Founded
- 2022
- Employees
- 13
- Website
- zenith-tx.com/
- Ownership
- Privately Held (backing)
Zenith Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Zenith Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Zenith Therapeutics in its N-PORT filings yet. We sweep new filings monthly.